Alpha Tau Medical (NASDAQ:DRTSW – Get Free Report) is projected to release its results before the market opens on Tuesday, August 18th. Analysts expect Alpha Tau Medical to post earnings of ($0.1409) per share and revenue of $0.1440 million for the quarter.
Alpha Tau Medical Stock Performance
DRTSW stock opened at $3.46 on Tuesday. Alpha Tau Medical has a fifty-two week low of $0.20 and a fifty-two week high of $4.28. The company has a 50 day moving average price of $2.78 and a 200 day moving average price of $1.79.
About Alpha Tau Medical
Alpha Tau Medical Ltd. is a clinical-stage medical technology company focused on the development of alpha-emitting radiation therapy for the treatment of solid tumor cancers. The company’s proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform leverages the short-range, high-energy alpha particles emitted by radium-224 to penetrate tumor tissues more effectively than conventional external-beam radiation. By implanting thin, needle-like sources directly into a tumor, Alpha DaRT delivers concentrated doses of radiation to malignant cells while sparing surrounding healthy tissue.
The Alpha DaRT technology is designed to enhance local tumor control in a variety of solid tumors, including head and neck, breast, skin, and pancreatic cancers.
See Also
- Five stocks we like better than Alpha Tau Medical
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
